Traumatic Brain Injury (TBI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

April 12, 2011 - PRLog -- GlobalData estimated the traumatic brain injury (TBI) therapeutics market in 2010 to be worth $1.54 billion and forecasts it to grow at 3.8% annually for the next seven years to reach $2 billion by 2017. This significant growth is primarily attributed to increasing therapeutic options for the treatment of TBI. The entry of some molecular targeted therapies such as BHR-100 (progesterone) and Recombinant human erythropoietin (rhuEpo), currently in Phase III and NeuroSTAT (cyclosporine), currently in Phase I, may significantly stimulate market growth in the near future. However, poor societal awareness, delayed diagnosis and underfunding of TBI research will continue to be a barrier for the TBI therapeutics market.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Traumatic-Brain-Injury-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

GlobalData analysis points out that the current competition in the TBI therapeutics market is weak as the market lacks therapies approved by the FDA (Food and Drug Administration) or the EMEA (European Medicines Agency) for the treatment of TBI. This is mainly due to the non-specific symptoms of the disease which hinder the diagnosis of the disease at an early stage. The off-label use of drugs such as Osmitrol (mannitol) to reduce the Intracranial Pressure (ICP) and NovoSeven to treat coagulopathy do not serve the market’s unmet needs completely. The market has no neuroprotective, neurorestorative and symptomatic treatment options available that can treat the disease completely. This clearly signifies that the current competition in the TBI market is weak.

GlobalData analysis found that there are 41 products in different stages of development. Progesterone and rhuEpo currently in Phase III are the most promising products in the pipeline. Cyclosporine, which is in Phase III, has been granted orphan drug status and is expected to enter the market in 2013. These molecules have shown encouraging response rates in pretreated patients and aim to prevent the cascade of physiological events that occur over a period of hours or days following the initial damage to the brain. These products are expected to meet some of the unmet needs and will provide physicians with better treatment options. The TBI therapeutics market may subsequently be more competitive in future.

GlobalData, the industry analysis specialist, has released its new report, “Traumatic Brain Injury (TBI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Traumatic Brain Injury Therapeutics market. The report identifies the key trends shaping and driving the global Traumatic Brain Injury Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Traumatic Brain Injury Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Trau...

Visit our report store: http://www.globaldata.com

For more details contact:
pressreleases@globaldata.com            
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage including oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries.